VISTAGEN THERAP. DL-,001

Vistagen has appointed Dr. Douglas J. Williamson to its board. Williamson brings nearly three decades of experience in neuroscience, clinical development and regulatory strategy and is the founder of Destiny Biopharm Consulting. Previously he was chief medical officer at QurAlis and held leadership roles at Acadia, Avadel, H. Lundbeck, Parexel and Eli Lilly. Vistagen is developing intranasal, late‑stage drug candidates such as Fasedienol, Itruvon and Refisolon. » Más en de.investing.com

Vistagen Therapeutics said that Margaret FitzPatrick and Dr. Joanne Curley will not stand for re-election at the 2026 annual meeting and will continue to serve until then. The company gave no reasons for the resignations or potential successors. The announcement comes during a period of high stock volatility after the share price recently rose by almost 29%, but remains well down year-to-date. Vistagen also reported progress in its clinical programs, including safety data on fasedienol, preliminary PALISADE-3 data, completion of recruitment for PALISADE-4, and the appointment of a new CMO. » Más en de.investing.com

Vistagen approved stock options for all employees, including key executives, as a retention measure and on April 7 granted individual executives options for up to 75,000 common shares. The options were issued with an exercise price of $0.5358; 25% vest after six months, the remainder in three further instalments every six months, fully vested after two years. The measure follows an approximately 85% decline in the share price over six months; Vistagen reported cash and cash equivalents of $61.2 million as of December 31, 2025, plans a 20% workforce reduction and expects topline results from the Phase 3 PALISADE-4 study in H1 2026. The company also reports non-compliance with a NASDAQ listing rule due to board and committee vacancies and is seeking new directors. » Más en de.investing.com